Experimental boron neutron capture therapy for melanoma: systemic delivery of boron to melanotic and amelanotic melanoma.
Experimental boron neutron capture therapy for melanoma: systemic delivery of boron to melanotic and amelanotic melanoma.
复制标题
黑色素瘤的实验性硼中子捕获疗法：将硼全身输送至黑色素和无黑色素瘤。
DOI：
10.1111/j.1600-0749.1990.tb00303.x
复制
发表时间：
1990
期刊：
影响因子：
--
通讯作者：
Greenberg,D
中科院分区：
文献类型：
--
作者：
Coderre,JA;Glass,JD;Packer,S;Micca,P;Greenberg,D
含硼黑色素前体类似物表硼苯丙氨酸（BPA）先前已被证明在单次胃内给药时可选择性地将硼递送至色素性小鼠黑色素瘤。如果硼中子俘获疗法要成为临床上有用的人类恶性黑色素瘤放射疗法的方法，硼载体必须能够将有用量的硼递送到远处肿瘤部位（转移瘤）和着色不良的黑色素瘤。我们现在已经确定了BPA在几种非色素性黑色素瘤模型（包括裸鼠的人黑色素瘤异种移植物）中蓄积的能力。在非色素性黑色素瘤中硼的绝对量约为在色素性黑色素瘤中观察到的硼的绝对量的50%，但相对于正常组织，硼仍选择性地集中在肿瘤中，其量足以进行有效的中子捕获治疗。单次胃内注射BPA会导致兔眼前房中携带的无色素性格林黑色素瘤和肺部生长的色素性小鼠黑色素瘤中的硼选择性定位。这些肿瘤中的硼浓度与紧邻正常组织中的硼浓度之比在3：1至4：1的范围内。这些分布研究支持硼中子俘获疗法可能作为恶性黑色素瘤的区域疗法的建议。
The boron‐containing melanin precursor analoguep‐boronophenylalanine (BPA) has previously been shown to selectively deliver boron to pigmented murine melanomas when administered in a single intragastric dose. If boron neutron capture therapy is to become a clinically useful method of radiation therapy for human malignant melanoma, the boron carrier must be capable of delivering useful amounts of boron to remote tumor sites (metastases) and to poorly pigmented melanomas. We have now determined the ability of BPA to accumulate in several nonpigmented melanoma models including human melanoma xenografts in nude mice. The absolute amount of boron in the nonpigmented melanomas was about 50% of that observed in the pigmented counterparts but was still selectively concentrated in the tumor relative to normal tissues in amounts sufficient for effective neutron capture therapy. Single intragastric doses of BPA resulted in selective localization of boron in the amelanotic Greene melanoma carried in the anterior chamber of the rabbit eye and in a pigmented murine melanoma growing in the lungs. The ratio of the boron concentration in these tumors to the boron concentration in the immediately adjacent normal tissue was in the range of 3:1 to 4:1. These distribution studies support the proposal that boron neutron capture therapy may be useful as a regional therapy for malignant melanoma.